Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 16/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7137016 | 0.87 | CRHR1 (0.44) | CRHR1 | |
| SCHEMBL7081026 | 0.82 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL2873955 | 0.82 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL7136998 | 0.79 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL2872391 | 0.78 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL2869314 | 0.78 | CNR1 (0.46) | CRHR1 | |
| Hydrochloric Acid SCHEMBL2872047 | 0.78 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL7081174 | 0.78 | DPP4 (0.43) | CRHR1 | |
| Hydrochloric Acid SCHEMBL2864749 | 0.77 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL2869643 | 0.77 | CRHR1 (0.45) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220342-A1 | Imidazo[1, 2-a] pyrazines for the treatment of irritable bowel syndrome | BAKTHAVATCHALAM RAJAGOPAL (US) | 2003-11-27 | — | — | US | disclosed |
| US-6589952-B2 | Imidazo(1,2-a)pyrazines containing an aryl or heteroaryl group are useful as (corticotropin releasiang factor) CRF receptor antagonists in the treatment of various neurological and psychological disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-08 | — | — | US | disclosed |
| EP-1301511-A2 | IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Bristol-Myers Squibb Pharma Company (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020049208-A1 | Imidazo[1,2-a]pyrazines for the treatment of neurological disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-25 | — | — | US | disclosed |
| WO-2002006286-A2 | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220342-A1 | Imidazo[1, 2-a] pyrazines for the treatment of irritable bowel syndrome | SCN5A, HRH2, CHRNA5 | CRHR1 64/4885 |
| US-20020049208-A1 | Imidazo[1,2-a]pyrazines for the treatment of neurological disorders | CRHR1, CRHR2, CRH | CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.